Evgen Pharma
plc
("Evgen",
the "Company" or the "Group")
Director / PDMR
Shareholding
5 April 2024 - Evgen Pharma plc (AIM: EVG), the clinical stage drug
development company developing sulforaphane based medicines for the
treatment of multiple diseases, announces that certain
Directors and Persons Discharging Managerial Responsibility
("PDMRs") have subscribed for new Ordinary Shares amounting to an
aggregate subscription for 8,600,000 new Ordinary Shares through
the Placing or the Subscription or pursuant to the terms of the
Acquisition announced on 19 March 2024, as follows:
|
Director
|
Number of Existing Ordinary
Shares held
|
Number of New Ordinary
Shares being subscribed
|
Number of Initial
Consideration Shares being allotted pursuant to the
Acquisition
|
Total number of Ordinary
Shares immediately following Admission
|
Percentage of Issued Share
Capital following Admission
|
|
Dr Huw Jones (CEO)
|
62,500
|
3,000,000
|
122,293**
|
3,184,793
|
0.75%
|
|
Toni Hänninen (CFO)*
|
0
|
1,000,000
|
0
|
1,000,000
|
0.23%
|
|
Dr Susan Foden (Chair)
|
125,000
|
600,000
|
0
|
725,000
|
0.17%
|
|
Dr Helen Kuhlman (PDMR)
|
55,744
|
1,000,000
|
0
|
1,055,744
|
0.25%
|
|
Dr Glen Clack (PDMR)***
|
0
|
1,000,000
|
0
|
1,000,000
|
0.23%
|
|
Dr Nicholas Mallard
(PDMR)
|
20,771
|
2,000,000
|
0
|
2,020,771
|
0.47%
|
*Toni Hänninen participated via Borealito GmbH (a company
wholly owned by him).
**
Dr Huw Jones has a shareholding of 96,350 shares in Chronos
Therapeutics and will as result be receiving 122,293 Initial
Consideration Shares in Evgen on completion of the
Acquisition.
***Dr Glen Clack participated via Ailse Oncology Ltd (a
company wholly owned by him).
Unless otherwise defined
herein, terms used in this announcement
have the meaning given to them in the Acquisition, Fundraising and
Change of Name announcement dated 19 March 2024.
Enquiries
|
Evgen Pharma plc
Dr Huw Jones, CEO
Toni Hänninen, CFO
Dr Helen Kuhlman, CBO
|
+44 207 457
2020
enquiries@evgen.com
|
|
Cavendish Capital Markets (NOMAD and
Broker)
Geoff Nash / Teddy
Whiley / Rory Sale (Corporate Finance)
Nigel Birks / Harriet Ward
(ECM)
|
+44 20 7220
0500
|
|
Instinctif Partners
Melanie Toyne-Sewell / Jack
Kincade
|
+44 207 457 2020
Evgen@Instinctif.com
|
About Evgen Pharma plc
Evgen Pharma is a clinical stage
drug development company developing sulforaphane based medicines
for the treatment of multiple diseases. The Company's core
technology is Sulforadex®, a method for synthesising and
stabilising the highly biologically active compound sulforaphane
and novel proprietary analogues based on sulforaphane.
The Company's lead asset, SFX-01, is
a patented composition of synthetic sulforaphane and
alpha-cyclodextrin and has undergone clinical trials for
oestrogen-positive (ER+) metastatic breast cancer and recently a
Phase 1b study of the Company's new enteric coated tablet
formulation. The FDA has granted Orphan Drug status to SFX-01 in
malignant glioma. SFX-01 will be investigated initially in this
indication as an investigator sponsored study in the
Netherlands.
The Company also has a wide number
of collaborations with leading academic centres in the UK, Europe
and the US as part of the continuing strategy to build the
scientific data for the compound. Recently, Evgen completed an
out-licensing transaction with Stalicla SA, a Swiss specialist
company in neurodevelopmental disorders, commencing with autism
spectrum disorder. The deal, if successful, will generate milestone
payments of $160.5m and a double-digit royalty on sales.
The Company has its headquarters and
registered office at Alderley Park, Cheshire. It is listed on AIM
in London and trades under the ticker symbol EVG.
For further information, please
visit: www.evgen.com.
Accordingly, the Company makes the following announcement and
notification in accordance with the EU Market Abuse Regulation (No
596/2014):
|
1.
|
Details of the person discharging managerial responsibilities
/ person closely associated
|
|
a)
|
Name
|
Dr Huw Jones
|
|
2.
|
Reason for the Notification
|
|
a)
|
Position/status
|
Chief Executive Officer
|
|
b)
|
Initial
notification/Amendment
|
Initial Notification
|
|
3.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
Evgen Pharma plc
|
|
b)
|
LEI
|
213800NO3E6TSTQO8K20
|
|
4.
|
Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii) each
date; and (iv) each place where transactions have been
conducted
|
|
a)
|
Description of the Financial
instrument, type of instrument
|
Ordinary Shares of 0.25p
each
|
|
Identification code
|
GB00BSVYN304
|
|
b)
|
Nature of the transaction
|
Purchase of new Ordinary Shares and
receipt of Consideration Shares
|
|
c)
|
Price(s) and volume(s)
|
|
Type
|
Price(s)
|
Volume(s)
|
|
Initial Consideration
Shares
|
1.44p
|
122,293
|
|
Placing Shares
|
1p
|
3,000,000
|
|
|
d)
|
Aggregated information:
· Aggregated
volume
· Price
|
As above
|
|
e)
|
Date of the transaction
|
5 April 2024
|
|
f)
|
Place of the transaction
|
London Stock Exchange, AIM
Market
|
|
1.
|
Details of the person discharging managerial responsibilities
/ person closely associated
|
|
a)
|
Name
|
Toni Hänninen
|
|
2.
|
Reason for the Notification
|
|
a)
|
Position/status
|
Chief Financial Officer
|
|
b)
|
Initial
notification/Amendment
|
Initial Notification
|
|
3.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
Evgen Pharma plc
|
|
b)
|
LEI
|
213800NO3E6TSTQO8K20
|
|
4.
|
Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii) each
date; and (iv) each place where transactions have been
conducted
|
|
a)
|
Description of the Financial
instrument, type of instrument
|
Ordinary Shares of 0.25p
each
|
|
Identification code
|
GB00BSVYN304
|
|
b)
|
Nature of the transaction
|
Purchase of new Ordinary
Shares
|
|
c)
|
Price(s) and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
1p
|
1,000,000
|
|
|
d)
|
Aggregated information:
· Aggregated
volume
· Price
|
As above
|
|
e)
|
Date of the transaction
|
5 April 2024
|
|
f)
|
Place of the transaction
|
London Stock Exchange, AIM
Market
|
|
1.
|
Details of the person discharging managerial responsibilities
/ person closely associated
|
|
a)
|
Name
|
Dr Susan Foden
|
|
2.
|
Reason for the Notification
|
|
a)
|
Position/status
|
Non-Executive Chair
|
|
b)
|
Initial
notification/Amendment
|
Initial Notification
|
|
3.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
Evgen Pharma plc
|
|
b)
|
LEI
|
213800NO3E6TSTQO8K20
|
|
4.
|
Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii) each
date; and (iv) each place where transactions have been
conducted
|
|
a)
|
Description of the Financial
instrument, type of instrument
|
Ordinary Shares of 0.25p
each
|
|
Identification code
|
GB00BSVYN304
|
|
b)
|
Nature of the transaction
|
Purchase of new Ordinary
Shares
|
|
c)
|
Price(s) and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
1p
|
600,000
|
|
|
d)
|
Aggregated information:
· Aggregated
volume
· Price
|
As above
|
|
e)
|
Date of the transaction
|
5 April 2024
|
|
f)
|
Place of the transaction
|
London Stock Exchange, AIM
Market
|
|
1.
|
Details of the person discharging managerial responsibilities
/ person closely associated
|
|
a)
|
Name
|
Dr Helen Kuhlman
|
|
2.
|
Reason for the Notification
|
|
a)
|
Position/status
|
Chief Business Office /
PDMR
|
|
b)
|
Initial
notification/Amendment
|
Initial Notification
|
|
3.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
Evgen Pharma plc
|
|
b)
|
LEI
|
213800NO3E6TSTQO8K20
|
|
4.
|
Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii) each
date; and (iv) each place where transactions have been
conducted
|
|
a)
|
Description of the Financial
instrument, type of instrument
|
Ordinary Shares of 0.25p
each
|
|
Identification code
|
GB00BSVYN304
|
|
b)
|
Nature of the transaction
|
Purchase of new Ordinary
Shares
|
|
c)
|
Price(s) and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
1p
|
1,000,000
|
|
|
d)
|
Aggregated information:
· Aggregated
volume
· Price
|
As above
|
|
e)
|
Date of the transaction
|
5 April 2024
|
|
f)
|
Place of the transaction
|
London Stock Exchange, AIM
Market
|
|
1.
|
Details of the person discharging managerial responsibilities
/ person closely associated
|
|
a)
|
Name
|
Glen Clack
|
|
2.
|
Reason for the Notification
|
|
a)
|
Position/status
|
Chief Medical Officer /
PDMR
|
|
b)
|
Initial
notification/Amendment
|
Initial Notification
|
|
3.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
Evgen Pharma plc
|
|
b)
|
LEI
|
213800NO3E6TSTQO8K20
|
|
4.
|
Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii) each
date; and (iv) each place where transactions have been
conducted
|
|
a)
|
Description of the Financial
instrument, type of instrument
|
Ordinary Shares of 0.25p
each
|
|
Identification code
|
GB00BSVYN304
|
|
b)
|
Nature of the transaction
|
Purchase of new Ordinary
Shares
|
|
c)
|
Price(s) and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
1p
|
1,000,000
|
|
|
d)
|
Aggregated information:
· Aggregated
volume
· Price
|
As above
|
|
e)
|
Date of the transaction
|
5 April 2024
|
|
f)
|
Place of the transaction
|
London Stock Exchange, AIM
Market
|
|
1.
|
Details of the person discharging managerial responsibilities
/ person closely associated
|
|
a)
|
Name
|
Dr Nicholas Mallard
|
|
2.
|
Reason for the Notification
|
|
a)
|
Position/status
|
PDMR
|
|
b)
|
Initial
notification/Amendment
|
Initial Notification
|
|
3.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
Evgen Pharma plc
|
|
b)
|
LEI
|
213800NO3E6TSTQO8K20
|
|
4.
|
Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii) each
date; and (iv) each place where transactions have been
conducted
|
|
a)
|
Description of the Financial
instrument, type of instrument
|
Ordinary Shares of 0.25p
each
|
|
Identification code
|
GB00BSVYN304
|
|
b)
|
Nature of the transaction
|
Purchase of new Ordinary
Shares
|
|
c)
|
Price(s) and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
1p
|
2,000,000
|
|
|
d)
|
Aggregated information:
· Aggregated
volume
· Price
|
As above
|
|
e)
|
Date of the transaction
|
5 April 2024
|
|
f)
|
Place of the transaction
|
London Stock Exchange, AIM
Market
|